Investors Urged to Act in ADMA Biologics Securities Fraud Lawsuit
Investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to seek lead plaintiff status in a securities fraud class action lawsuit filed by The Rosen Law Firm.
New York – Investors who purchased securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024, and March 25, 2026, inclusive, are reminded of an important lead plaintiff deadline in a securities fraud class action lawsuit. The Rosen Law Firm, an international investor rights law firm, has set August 10, 2026, as the deadline for potential lead plaintiffs to file with the court.
The lawsuit alleges that ADMA Biologics executives made materially false and misleading statements. Specifically, the complaint claims the company engaged in undisclosed related party transactions, used channel stuffing to inflate revenues, and lacked adequate internal controls. These alleged misrepresentations and omissions, according to the suit, resulted in financial damages to investors when the true facts became public.
The Rosen Law Firm is encouraging investors who experienced losses to come forward. The firm, which concentrates its practice on securities class actions, states that individuals who wish to serve as lead plaintiff must file a motion with the court by the August 10 deadline. A lead plaintiff plays a representative role in directing the litigation on behalf of other class members.
Interested investors can obtain more information about the class action and their potential to recover losses through a contingency fee arrangement, meaning no out-of-pocket costs for clients. The firm has provided contact details for those seeking to join the lawsuit or learn more about their legal options.